Big Data Platform

The Dry Lab™️

  • Our pioneering multi-omics research platform intergrating molecular genomics, stem cells, bioinformatics and AI for actionable disease management outcomes
Read more

Biomarker Discovery

The Avestagenome Project®

Largest global epidemiology and molecular genomics driven study of an endogamous population for with actionable outcomes in healthcare

Read more

Harnessing Genomic Potential

Genetic Risk Factors

Our classified cohort has the potential to deliver the holy grail of genomics - Predictive, Preventive, Personalized medicines for global populations

Read more

AGENOME LLC is a US based leading population genomics and life sciences company addressing longevity, using the unique Zoroastrian-Parsi community blood biobank and patient databank as a control population to accelerate the identification of biomarkers and druggable targets. With the highest global ethical standards, AGENOME delivers research outcomes leading to Predictive, Preventive and Personalized (“PPP”) healthcare by leveraging insights from The Avestagenome Project®.  Our study is a community based, discovery driven, systems biology initiative of unique populations. AGENOME investigates the molecular basis of longevity and age-related disorders, prioritizing cancers, cardiovascular disease, diabetes, neurological disorders with the goal of providing personalized, patient centric diagnostics.

Genomics Biobank for Population-Driven Therapeutics

Blood Collection

Creation of the world's first systems biology led biorepository of the genetically well defined Zoroastrian-Parsis. Housing 4700+ samples. Samples are collected from volunteers and stored at -80℃. DNA, RNA, plasma and stem cells are extracted for further analyses. All samples are barcoded and anonymised upon receipt.

Liquid biopsy

Non-invasive genetic predisposition screening from plasma and whole blood. High depth sequencing at 5000X for circulating free DNA using a propriety capture panel. Tertiary analysis or disease mapping is done through a clinical variant prioritization platform ensuring rapid turn around and accurate reports.

NEXTGEN Sequencing

Whole genome, whole exome, targeted panel based sequencing using state-of-the-art Illumina platforms. Offering turn key clinical genomic analysis and reporting with our exclusive partner Congenica® - the world’s leading software for the analysis, interpretation and reporting of genomic data.

We invest in the future

Building a Genomics Biobank for the deep understanding of molecular mechanisms involved in disease onset based on population genetics. The 10,000 Avestagenome Project® is a systems biology study that aims to understand the molecular basis of longevity in the Zoroastrian-Parsi population using NEXTGEN Sequencing Technology to identify critical disease associated genomic variants that underscore the health of this community.

Biomarker Discovery

For predictive diagnostics and targeted novel drug therapies

Stem Cell Platform

IPSC stem cells immortilized and/or frozen for drug discovery and personalized regenerative medicine

Biorepository

Ensuring the highest ethical standards and strict confidentiality of all participant information

Precision Medicine

Leveraging decades of R&D expertise from partner The Avestagenome Project®

The Avestagenome Project® was created to identify within the Parsi population genetic risk factors that predispose individuals to cancers, elucidate gene function and improve public health through early intervention, improving disease prevention strategies and delivering improved population and patient health outcomes. It is the largest epidemiological study ever conducted on a consanguineous population and the first detailed system biology study worldwide on an endogamous population. The project has collected a biobank of blood samples with extensive patient data from its first cohort of 4,700 Parsis and is dedicated to the identification and delivery of predictive biomarkers and druggable targets.

Our Journey So Far

The Avestagenome Project® was conceptualised with the intent of building a complete genealogical, medical and genetic database of the Parsi population in India. The Avestagenome Project® is continually identifying unique variants linked to various disease onsets, potentially enhancing our understanding of the genetic mechanisms involved. Studies such as these provide valuable outcomes that help build and enhance public health frameworks for disease prevention strategies through early intervention for global populations at large.

In a landmark first, The Avestagenome Project® has successfully sequenced and assembled the full length female and male Zoroastrian-Parsi nuclear genomic reference standard, AGENOME-ZPGRF and AGENOME-ZPGRM. Additionally, we generated the first complete de novo Zoroastrian Mitochondrial Reference Genome, AGENOME-ZPMSHV2a-1. Our research expands the understanding of the implications of genomic signatures in an endogamous population, accelerating the development of Predictive, Precise and Personalized medicine for all humankind.

Our research, which has thus far traced ancestry via the mitochondrial genome and environmental cues affecting individual epigenomes, is now exploring the nuclear genome, the genetic code of life. We are confident that this milestone will identify risk by diagnosing disease, such as cancers, neurodegenerative conditions, and rare disorders, while mitigating the risk through customising treatment regimens.

View the Latest News

Stay up to date to find out how The Avestagenome Project® is leading to groundbreaking insights with continued findings into the role of genomics in Precision Medicine.